Abilify MyCite: Withdrawal of the marketing authorisation application



Otsuka Pharmaceutical Netherlands B.V. withdrew its application for a marketing authorisation of Abilify MyCite for the treatment of schizophrenia and bipolar I disorder.

The company withdrew the application on 17 July 2020.

Key facts

Abilify MyCite
Product number
International non-proprietary name (INN) or common name
  • aripiprazole
Active substance
  • aripiprazole
Date of withdrawal
Company making the application
Otsuka Pharmaceutical Netherlands B.V.
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating